1. Home
  2. OBLG vs VCNX Comparison

OBLG vs VCNX Comparison

Compare OBLG & VCNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OBLG
  • VCNX
  • Stock Information
  • Founded
  • OBLG 2000
  • VCNX 2001
  • Country
  • OBLG United States
  • VCNX United States
  • Employees
  • OBLG N/A
  • VCNX N/A
  • Industry
  • OBLG Computer Software: Programming Data Processing
  • VCNX Biotechnology: Pharmaceutical Preparations
  • Sector
  • OBLG Technology
  • VCNX Health Care
  • Exchange
  • OBLG Nasdaq
  • VCNX Nasdaq
  • Market Cap
  • OBLG 3.8M
  • VCNX 4.5M
  • IPO Year
  • OBLG N/A
  • VCNX N/A
  • Fundamental
  • Price
  • OBLG $3.77
  • VCNX $3.22
  • Analyst Decision
  • OBLG
  • VCNX
  • Analyst Count
  • OBLG 0
  • VCNX 0
  • Target Price
  • OBLG N/A
  • VCNX N/A
  • AVG Volume (30 Days)
  • OBLG 61.2K
  • VCNX 167.3K
  • Earning Date
  • OBLG 11-07-2024
  • VCNX 11-29-2024
  • Dividend Yield
  • OBLG N/A
  • VCNX N/A
  • EPS Growth
  • OBLG N/A
  • VCNX N/A
  • EPS
  • OBLG N/A
  • VCNX N/A
  • Revenue
  • OBLG $2,759,000.00
  • VCNX $388,000.00
  • Revenue This Year
  • OBLG N/A
  • VCNX N/A
  • Revenue Next Year
  • OBLG N/A
  • VCNX N/A
  • P/E Ratio
  • OBLG N/A
  • VCNX N/A
  • Revenue Growth
  • OBLG N/A
  • VCNX N/A
  • 52 Week Low
  • OBLG $2.81
  • VCNX $1.39
  • 52 Week High
  • OBLG $14.80
  • VCNX $13.02
  • Technical
  • Relative Strength Index (RSI)
  • OBLG 47.74
  • VCNX 48.87
  • Support Level
  • OBLG $3.70
  • VCNX $2.87
  • Resistance Level
  • OBLG $4.14
  • VCNX $3.43
  • Average True Range (ATR)
  • OBLG 0.26
  • VCNX 0.53
  • MACD
  • OBLG 0.04
  • VCNX 0.05
  • Stochastic Oscillator
  • OBLG 50.00
  • VCNX 23.22

About OBLG Oblong Inc.

Oblong Inc is a provider of patented multi-stream collaboration products and managed services for video collaboration and network solutions. The company's flagship product Mezzanine is the technology platform that defines computing: simultaneous multi-user, multi-screen, multi-device, and multi-location for dynamic and immersive visual collaboration. Mezzanine transforms routine meetings and workflows into agile, engaging experiences by making data visible and accessible in a collaborative setting. Mezzanine enables multiple, concurrent pieces of content to be shared, manipulated, created, and captured across distance. It serves various industries including aerospace, consulting, executive search, broadcast media, technology, financial services, education, healthcare, real estate.

About VCNX Vaccinex Inc.

Vaccinex Inc is pioneering a differentiated approach to treating cancer and slowly progressive neurodegenerative diseases through the inhibition of semaphorin 4D (SEMA4D). The company's lead drug candidate, pepinemab, blocks SEMA4D, a potent biological effector that it believes prevents immune infiltration into tumors and triggers inflammation in chronic diseases of the brain. Pepinemab is being evaluated in a Phase 1b/2 study in recurrent or metastatic head and neck cancer and in a Phase 1/2a study in Alzheimer's Disease, with ongoing exploration of potential Phase 3 development in Huntington's disease. The firm has also developed a proprietary drug discovery platform, ActivMAb.

Share on Social Networks: